Soleno Therapeutics, founded in Redwood City, United States, is a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics for rare diseases. The company's core mission is to address the unmet medical needs of patients with rare genetic disorders, with a particular focus on conditions like Prader-Willi syndrome. Soleno's vision is to improve the quality of life for patients and their families by providing innovative and effective treatments.

Notable figures affiliated with Soleno Therapeutics include experienced professionals in the biopharmaceutical industry, although specific names are not provided. The company has garnered attention from investors due to its promising pipeline and focus on rare diseases, a niche yet impactful market. Key achievements include advancing their lead candidate through clinical trials and building a robust portfolio aimed at addressing significant gaps in treatment options for rare genetic disorders. Soleno's work has had a meaningful impact on the rare disease community, offering hope and potential new therapies for patients who have limited treatment options.